Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures

Prior treatment

• Patients currently taking, or having taken within the previous 1 month, armodafinil, modafinil, amphetamine, or methylphenidate.
• Patients who are enrolled and receiving active treatment in a symptom intervention trial or who are in the treatment phase of a clinical trial.

Other illness

• Patients with clinical evidence of active persistent cancer or progressive disease after completing planned cancer therapy, or with active recurrent cancer.
• Patients with underlying cardiac or pulmonary disease resulting in dyspnea, hypoxia, or hypercapnia.
• Patients with major depressive disorder or severe depression (a score of 22 or greater on the Center for Epidemiologic Studies Depression (CES-D)); for scores of 16 or higher, we will notify the patient's treating physician within 1 working day of the screening to allow for appropriate management or referral.

Other

• Patients with potential medical or other underlying causes of fatigue, as determined by the treating physician or Principal Investigator.
• Patients experiencing moderate to severe pain (4 or higher on a 0 to 10 scale) at the time of screening.
• Patients who cannot distinguish between the red and blue stimuli of the set-switch task.

• Male patients at least 18 years old.
• Patients who completed either definitive or postoperative radiation or chemoradiation therapy for head and neck cancer within the past 6 weeks to 120 months.
• Patients who speak English.
• Patients who are willing and able to review, understand, and provide written consent.
• Patients who agree to comply with all study procedures.